The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 19, 2020

Filed:

Jul. 26, 2017
Applicant:

Agency for Science, Technology and Research, Singapore, SG;

Inventors:

Simeon Cua, Singapore, SG;

Andre Boon Hwa Choo, Singapore, SG;

Heng Liang Tan, Singapore, SG;

Wey Jia Fong, Singapore, SG;

Vanessa Mei Yee Ding, Singapore, SG;

Leonard Wen Yan Leong, Singapore, SG;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/18 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/5377 (2006.01); A61K 38/17 (2006.01); C07K 14/705 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/5377 (2013.01); A61K 38/1774 (2013.01); A61K 39/3955 (2013.01); A61K 47/6819 (2017.08); A61K 47/6825 (2017.08); A61K 47/6843 (2017.08); A61P 35/00 (2018.01); C07K 14/70521 (2013.01); G01N 33/574 (2013.01); A61K 2039/505 (2013.01); A61K 2039/572 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/40 (2013.01); C07K 2317/54 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/77 (2013.01); C07K 2317/90 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); G01N 2333/4718 (2013.01);
Abstract

The present invention relates to an antigen-binding protein, preferably a monoclonal antibody, against annexin A2 (ANXA2), comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence GYSITSGYSWH, a VHCDR2 of sequence YIHYSGSTKYNPSLKS and a VHCDR3 of sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSNDQKNYLA, a VLCDR2 of sequence WASIRES, and a VLCDR3 of sequence QQYYIYPLT. Also provided is an ANXA2 binding protein comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence VYSITSGYSWH; a VHCDR2 of sequence YIHYSGSTKYNPSLKS, and a VHCDR3 of sequence GTDNAVDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSSNQKNYLA, a VLCDR2 of sequence WASSRES, and a VLCDR3 of sequence QQYYIYPLT. The antibodies preferably bind to an N-linked glycan on ANXA2, and are internalised upon binding. They may be conjugated with cytotoxins and may be used in the treatment or detection of cancer.


Find Patent Forward Citations

Loading…